Tag: HFpEF
Occlutech starts patient dosing in the FROST study to look into using an atrial flow regulator to treat heart failure with preserved ejection fraction (HFpEF).
One of the top manufacturers of minimally invasive structural heart disease devices, Occlutech Holding AG (Occlutech), has announced…
Registration Form
This will close in 0 seconds
